Proteomic investigations into resistance in colorectal cancer

References

• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Web collection - Colorectal Cancer. [cited 13 Sept 2019]. Available from: https://www.nature.com/collections/mzwkvsswmr
   Google Scholar
• Chauvin A, Boisvert FM. Clinical proteomics in colorectal cancer, a promising tool for improving personalised medicine. Proteomes. 2018;6(4):49.
   PubMed Web of Science ®Google Scholar
• Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84.
   PubMed Web of Science ®Google Scholar
• Edwards BK, Noone A-M, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–1314.
   PubMed Web of Science ®Google Scholar
• Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–117.
   PubMed Web of Science ®Google Scholar
• Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275–292.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humbet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–345.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–1664.
   PubMed Web of Science ®Google Scholar
• Kathawala RJ, Gupta P, Ashby CR, et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1–17.
   PubMed Web of Science ®Google Scholar
• Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies. Oncologist. 2012;17(8):1039–1050.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193.
   PubMed Web of Science ®Google Scholar
• Cao D, Qin S, Mu Y, et al. The role of MRP1 in the multidrug resistance of colorectal cancer. Oncol Lett. 2017;13(4):2471–2476.
   PubMed Web of Science ®Google Scholar
• Briffa RL, Langdon SP, Grech G, et al. Acquired and intrinsic resistance to colorectal cancer treatment. Colorectal Cancer - Diagnosis, Screening and Management. Jindong Chen, IntechOpen. 2017. DOI: 10.5772/intechopen.70781. Available from: https://www.intechopen.com/books/colorectal-cancer-diagnosis-screening-and-management/acquired-and-intrinsic-resistance-to-colorectal-cancer-treatment.
   Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047.
   PubMed Web of Science ®Google Scholar
• Cheeseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87(4):393–399.
   PubMed Web of Science ®Google Scholar
• Pereira DM, Simões AES, Gomes SE, et al. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget. 2016;7(23):34322–34340.
   PubMedGoogle Scholar
• Weidlich S, Walsh K, Crowther D, et al. Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer. 2011;105(2):246–254.
   PubMed Web of Science ®Google Scholar
• Ahronian LG, Corcoran RB. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med. 2017;9(1):37.
   PubMedGoogle Scholar
• De Sousa EMF, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–618.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134(3):552–562.
   PubMed Web of Science ®Google Scholar
• Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–625.
   PubMed Web of Science ®Google Scholar
• Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29(1):17–24.
   PubMed Web of Science ®Google Scholar
• Van der Jeught K, Xu H-C, Li Y-J, et al. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834–3848.
   PubMed Web of Science ®Google Scholar
• Nicum S, Midgley R, Kerr DJ. Chemotherapy for colorectal cancer. J R Soc Med. 2000;93(8):416–419.
   PubMed Web of Science ®Google Scholar
• Abdallah EA, Fanelli MF, Buim MEC, et al. Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. Int J Cancer. 2015;137(6):1397–1405.
   PubMed Web of Science ®Google Scholar
• Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6(4):1322–1327.
   PubMed Web of Science ®Google Scholar
• Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15(10):3223–3229.
   PubMed Web of Science ®Google Scholar
• Qiu L-X, Tang Q-Y, Bai J-L, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer. 2008;123(10):2384–2389.
   PubMed Web of Science ®Google Scholar
• Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55(7):1407–1412.
   PubMed Web of Science ®Google Scholar
• Wang TL, Diaz LA, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A. 2004;101(9):3089–3094.
   PubMed Web of Science ®Google Scholar
• Che J, Pan L, Yang X, et al. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis. Mol Clin Oncol. 2017;7(6):943–952.
   PubMed Web of Science ®Google Scholar
• Yanagisawa Y, Maruta F, Iinuma N, et al. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. Scand J Gastroenterol. 2007;42(4):477–484.
   PubMed Web of Science ®Google Scholar
• Sakowicz-Burkiewicz M, Przybyla T, Wesserling M, et al. Suppression of TWIST1 enhances the sensitivity of colon cancer cells to 5-fluorouracil. Int J Biochem Cell Biol. 2016;78:268–278.
   PubMed Web of Science ®Google Scholar
• Lin S, Lai H, Qin Y, et al. Thymidine phosphorylase and hypoxia-inducible factor 1-alpha expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis. Int J Clin Exp Pathol. 2015;8(9):10680–10688.
   PubMed Web of Science ®Google Scholar
• Stark M, Bram EE, Akerman M, et al. Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance. J Biol Chem. 2011;286(5):3741–3754.
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Yang DY, Kuramochi H, et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol. 2007;31(2):413–418.
   PubMed Web of Science ®Google Scholar
• Chauvin A, Wang C-S, Geha S, et al. The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. Clin Proteomics. 2018;15:16.
   PubMed Web of Science ®Google Scholar
• Wang J, Mouradov D, Wang X, et al. Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology. 2017;153(4):1082–1095.
   PubMed Web of Science ®Google Scholar
• Poel D, Boyd LNC, Beekhof R, et al. Proteomic analysis of miR-195 and miR-497 replacement reveals potential candidates that increase sensitivity to oxaliplatin in MSI/P53wt Colorectal Cancer cells. Cells. 2019;8(9): 1111.
   PubMed Web of Science ®Google Scholar
• Palshof JA, Høgdall EVS, Poulsen TS, et al. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer. 2017;17(1):48.
   PubMedGoogle Scholar
• de Man FM, Goey AKL, van Schaik RHN, et al. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–1254.
   PubMed Web of Science ®Google Scholar
• Boyer J, McLean EG, Aroori S, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 2004;10(6):2158–2167.
   PubMed Web of Science ®Google Scholar
• Cummings J, Boyd G, Ethell BT, et al. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol. 2002;63(4):607–613.
   PubMed Web of Science ®Google Scholar
• Hector S, Bolanowska-Higdon W, Zdanowicz J, et al. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol. 2001;48(5):398–406.
   PubMed Web of Science ®Google Scholar
• Baba H, Watanabe M, Okabe H, et al. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. Br J Cancer. 2012;107(12):1950–1955.
   PubMed Web of Science ®Google Scholar
• Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19(23):4298–4304.
   PubMed Web of Science ®Google Scholar
• Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20(29):9775–9827.
   PubMed Web of Science ®Google Scholar
• Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66(17):8847–8857.
   PubMed Web of Science ®Google Scholar
• Meijer C, Mulder NH, Timmer-Bosscha H, et al. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992;52(24):6885–6889.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem. 1993;268(27):20116–20125.
   PubMed Web of Science ®Google Scholar
• Mao L, Li Y, Zhao J, et al. Transforming growth factor-beta1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition. Oncol Lett. 2017;14(1):647–654.
   PubMed Web of Science ®Google Scholar
• Sforza V, Martinelli E, Ciardiello F, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol. 2016;22(28):6345–6361.
   PubMed Web of Science ®Google Scholar
• Hsu HH, Chen M-C, Baskaran R, et al. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 2018;233(7):5458–5467.
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Uboha NV, Deming DA. Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol. 2017;8(3):499–512.
   PubMed Web of Science ®Google Scholar
• Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396.
   PubMed Web of Science ®Google Scholar
• Spier I, Horpaopan S, Vogt S, et al. Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. Hum Mutat. 2012;33(7):1045–1050.
   PubMed Web of Science ®Google Scholar
• Hong SN. Genetic and epigenetic alterations of colorectal cancer. Intest Res. 2018;16(3):327–337.
   PubMed Web of Science ®Google Scholar
• Kondo T, Hirohashi S. Application of 2D-DIGE in cancer proteomics toward personalized medicine. Methods Mol Biol. 2009;577:135–154.
   PubMedGoogle Scholar
• Rodrigo MA, Zitka O, Krizkova S, et al. MALDI-TOF MS as evolving cancer diagnostic tool: a review. J Pharm Biomed Anal. 2014;95:245–255.
   PubMed Web of Science ®Google Scholar
• Mesri M. Advances in proteomic technologies and its contribution to the field of cancer. Adv Med. 2014;2014:238045.
   PubMedGoogle Scholar
• McDonnell LA, Corthals GL, Willems SM, et al. Peptide and protein imaging mass spectrometry in cancer research. J Proteomics. 2010;73(10):1921–1944.
   PubMed Web of Science ®Google Scholar
• Schone C, Hofler H, Walch A. MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. Clin Biochem. 2013;46(6):539–545.
   PubMed Web of Science ®Google Scholar
• Muthu MV, Vimala A, Mendoza OH, et al. Tracing the voyage of SELDI-TOF MS in cancer biomarker discovery and its current depreciation trend – need for resurrection? Trends Analyt Chem. 2016;76:95–101.
   Web of Science ®Google Scholar
• Liu C. The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol. 2011;2011:245821.
   PubMedGoogle Scholar
• Anjo SI, Santa C, Manadas B. SWATH-MS as a tool for biomarker discovery: from basic research to clinical applications. Proteomics. 2017;17:3–4.
   Web of Science ®Google Scholar
• Sajic T, Liu Y, Aebersold R. Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin Appl. 2015;9(3–4):307–321.
   PubMed Web of Science ®Google Scholar
• Chambers AG, Percy AJ, Simon R, et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics. 2014;11(2):137–148.
   PubMed Web of Science ®Google Scholar
• You J, Kao A, Dillon R, et al. A large-scale and robust dynamic MRM study of colorectal cancer biomarkers. J Proteomics. 2018;187:80–92.
   PubMed Web of Science ®Google Scholar
• Westbrook JA, Noirel J, Brown JE, et al. Quantitation with chemical tagging reagents in biomarker studies. Proteomics Clin Appl. 2015;9(3–4):295–300.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Rozen P, Schuelke GS. Hereditary colon cancer: polyposis and nonpolyposis variants. CA Cancer J Clin. 1985;35(2):95–114.
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–2087 e3.
   PubMed Web of Science ®Google Scholar
• Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, et al. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench. 2013;6(3):120–128.
   PubMedGoogle Scholar
• Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382–387.
   PubMed Web of Science ®Google Scholar
• Monteleone F, Rosa R, Vitale M, et al. Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics. 2013;13(5):866–877.
   PubMed Web of Science ®Google Scholar
• Van Houdt WJ, Emmink BL, Pham TV, et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics. 2011;10(12):M111 011353.
   PubMed Web of Science ®Google Scholar
• Croner RS, Sevim M, Metodiev M, et al. Identification of predictive markers for response to neoadjuvant chemoradiation in rectal carcinomas by proteomic Isotope Coded Protein Label (ICPL) analysis. Int J Mol Sci. 2016;17(2):209.
   PubMed Web of Science ®Google Scholar
• Repetto O, De Re V, De Paoli A, et al. Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy. Oncotarget. 2017;8(17):28328–28341.
   PubMedGoogle Scholar
• Gong FM, Peng X-C, Tan B-X, et al. Comparative proteomic analysis of irinotecan-sensitive colorectal carcinoma cell line and its chemoresistant counterpart. Anticancer Drugs. 2011;22(6):500–506.
   PubMed Web of Science ®Google Scholar
• Sakai A, Otani M, Miyamoto A, et al. Identification of phosphorylated serine-15 and −82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics. J Proteomics. 2012;75(3):806–818.
   PubMed Web of Science ®Google Scholar
• McKinley ET, Liu H, McDonald WH, et al. Global phosphotyrosine proteomics identifies PKCdelta as a marker of responsiveness to Src inhibition in colorectal cancer. PLoS One. 2013;8(11):e80207.
   PubMed Web of Science ®Google Scholar
• Martin P, Noonan S, Mullen MP, et al. Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. BMC Cancer. 2014;14:887.
   PubMed Web of Science ®Google Scholar
• Katsila T, Juliachs M, Gregori J, et al. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin Cancer Res. 2014;20(24):6346–6356.
   PubMed Web of Science ®Google Scholar
• Clark CR, Starr TK. Mouse models for the discovery of colorectal cancer driver genes. World J Gastroenterol. 2016;22(2):815–822.
   PubMed Web of Science ®Google Scholar
• Georges LMC, De Wever O, Galván JA, et al. Cell line derived xenograft mouse models are a suitable in vivo model for studying tumor budding in colorectal cancer. Front Med (Lausanne). 2019;6:139.
   PubMed Web of Science ®Google Scholar
• Rosfjord E, Lucas J, Li G, et al. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 2014;91(2):135–143.
   PubMed Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.
   PubMed Web of Science ®Google Scholar
• Hansen DP, Dinger ME, Hofman O, et al. Preparing Australia for genomic medicine: data, computing and digital health. Med J Aust. 2019;210(Suppl 6):S30–S32.
   PubMedGoogle Scholar
• Yang Y, Dong X, Xie B, et al. Databases and web tools for cancer genomics study. Genomics Proteomics Bioinformatics. 2015;13(1):46–50.
   PubMed Web of Science ®Google Scholar
• Chen C, Huang H, Wu CH. Protein Bioinformatics Databases and Resources. Methods Mol Biol. 2017;1558:3–39.
   PubMedGoogle Scholar
• Higdon R, Earl RK, Stanberry L, et al. The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders. OMICS. 2015;19(4):197–208.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690.
   PubMed Web of Science ®Google Scholar
• Epstein RJ, Lin FP. Cancer and the omics revolution. Aust Fam Physician. 2017;46(4):189–193.
   PubMedGoogle Scholar
• Wang P, Berzin TM, Glissen Brown JR, et al. Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study. Gut. 2019;68(10):1813–1819.
   PubMed Web of Science ®Google Scholar
• Ahn SB, Sharma S, Mohamedali A, et al. Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel. Clin Proteomics. 2019;16:34.
   PubMed Web of Science ®Google Scholar
• Kyrochristos ID, Roukos DH. Comprehensive intra-individual genomic and transcriptional heterogeneity: evidence-based Colorectal Cancer precision medicine. Cancer Treat Rev. 2019;80:101894.
   PubMed Web of Science ®Google Scholar
• Martorell-Marugan J, Tabik S, Benhammou Y, et al. Deep learning in omics data analysis and precision medicine. In: Husi H, et al. editor. Computational Biology. Brisbane (AU): Codon Publiations, Chapter 3; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK550335/
   Google Scholar
• Vasaikar S, Huang C, Wang X, et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177(4):1035–1049 e19.
   PubMed Web of Science ®Google Scholar
• Jaffe JD, Berg HC, Church GM. Proteogenomic mapping as a complementary method to perform genome annotation. Proteomics. 2004;4(1):59–77.
   PubMed Web of Science ®Google Scholar
• Alfaro JA, Sinha A, Kislinger T, et al. Onco-proteogenomics: cancer proteomics joins forces with genomics. Nat Methods. 2014;11(11):1107–1113.
   PubMed Web of Science ®Google Scholar
• Imperial R, Ahmed Z, Toor OM, et al. Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. Mol Cancer. 2018;17(1):177.
   PubMedGoogle Scholar
• Ma YS, Huang T, Zhong XM, et al. Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Mol Cancer. 2018;17(1):139.
   PubMedGoogle Scholar
• Zhang B, Whiteaker JR, Hoofnagle AN, et al. Clinical potential of mass spectrometry-based proteogenomics. Nat Rev Clin Oncol. 2019;16(4):256–268.
   PubMed Web of Science ®Google Scholar
• Cheerla A, Gevaert O. Deep learning with multimodal representation for pan cancer prognosis prediction. Bioinformatics. 2019;35(14):i446–i454.
   PubMed Web of Science ®Google Scholar
• Cruz JA, Wishart DS. Applications of machine learning in cancer prediction and prognosis. Cancer Inform. 2007;2:59–77.
   PubMedGoogle Scholar
• Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17.
   PubMed Web of Science ®Google Scholar
• Madabhushi A, Lee G. Image analysis and machine learning in digital pathology: challenges and opportunities. Med Image Anal. 2016;33:170–175.
   PubMed Web of Science ®Google Scholar
• Madhavan D, Cuk K, Burwinkel B, et al. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116.
   PubMedGoogle Scholar
• Kel A, Boyarskikh U, Stegmaier P, et al. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer. BMC Bioinformatics. 2019;20(Suppl 4):119.
   PubMedGoogle Scholar
• Bychkov D, Linder N, Turkki R, et al. Deep learning based tissue analysis predicts outcome in colorectal cancer. Sci Rep. 2018;8(1):3395.
   PubMedGoogle Scholar
• Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115–118.
   PubMed Web of Science ®Google Scholar
• Janowczyk A, Madabhushi A. Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases. J Pathol Inform. 2016;7:29.
   PubMedGoogle Scholar
• Kelchtermans P, Bittremieux W, De Grave K, et al. Machine learning applications in proteomics research: how the past can boost the future. Proteomics. 2014;14(4–5):353–366.
   PubMed Web of Science ®Google Scholar
• Ayers D, Boughanem H, Macias-Gonzalez M. Epigenetic influences in the obesity/colorectal cancer axis: a novel theragnostic avenue. J Oncol. 2019;2019:7406078.
   PubMedGoogle Scholar
• Gao Z, Guo B, Gao R, et al. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–1089.
   PubMed Web of Science ®Google Scholar